Acalabrutinib - 2018 Launch Report with Sales Forecast to 2022 - ResearchAndMarkets.com

August 31, 2018

DUBLIN--(BUSINESS WIRE)--Aug 31, 2018--The “Acalabrutinib - Launch Insight, 2018” report has been added to ResearchAndMarkets.com’s offering.

Acalabrutinib, Launch Insight, 2018 report provides comprehensive Insight about the Acalabrutinib’s launch. The report covers all the indications for which the Acalabrutinib is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.

The report will provide a clear picture of market positioning of the upcoming launch of Acalabrutinib and will also provide the insight about how Acalabrutinib will evolve in the market as well as within its respective class. Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.

Key Topics Covered:

Report Introduction Acalabrutinib Overview Acalabrutinib of action Pre-clinical Characterization Clinical Characterization Product Developmental Activities Acalabrutinib Market Evolution Acalabrutinib Class Share Evolution Acalabrutinib Market Positioning Patent Expiry Analysis Competitive Landscape for the Acalabrutinib in major indications Appendix

For more information about this report visit https://www.researchandmarkets.com/research/bgh3qc/acalabrutinib?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180831005475/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/31/2018 04:08 PM/DISC: 08/31/2018 04:08 PM


Update hourly